Pre-order Enquiry
Request Free Sample
Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013
SKU ID : Azoth-13812998 | Publishing Date : 31-Jan-2019 | No. of pages : 240
Request Sample
Request Customization
Check Discounts
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.
According to Analytics research report “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, the antifungal drugs market is projected to display a robust growth represented by a CAGR of 3.70% during 2018 – 2023.
Over the recent years, Antifungal Drugs market has been witnessing growth on account of several driving factors including growing prevalence of fungal infections such as candidiasis and aspergillosis, increasing popularity of over-the-counter drugs, and increase in availability of innovative antifungals. Moreover, increasing awareness regarding fatal antifungal diseases, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, growing scope in developing countries with large population such as China and India is anticipated to impel the market growth of the antifungal drugs market. However, growing portfolio of antifungal generic drugs, patent expiration of innovator drugs, increasing prevalence of fungal resistance, and counterfeit drugs are expected to hinder the market performance during forecasted period.
In this research report, the market is segmented on the basis of drug class and therapeutic indications. By drug class, the azoles class antifungals are predicted to hold their dominant position in the market. By therapeutic indications, drugs use in the treatment of candidiasis are anticipated to creates their dominance in global antifungal drugs market. Amongst the regions, North America accounts for the largest regional share in the global antifungal drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and highly advanced medical infrastructure.
The report titled “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, has covered and analysed the potential of antifungal drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antifungal drugs. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Antifungal Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antifungal Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
• Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
Regional Antifungal Drugs Market – North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antifungal Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
• Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
Country Analysis – U.S., Canada, Germany, U.K, France, China, Japan, India (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antifungal Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
• Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
Other Report Highlights
• Market Dynamics – Drivers and Restraints.
• Market Trends.
• Porter Five Forces Analysis.
• SWOT Analysis.
• Company Analysis - Merck & Co., Glaxo Smith Kline, Astellas Pharma, Sanofi, Abbott Laboratories, Bayer, Kramer Laboratories, Novartis International AG, Pfizer.
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.
According to Analytics research report “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, the antifungal drugs market is projected to display a robust growth represented by a CAGR of 3.70% during 2018 – 2023.
Over the recent years, Antifungal Drugs market has been witnessing growth on account of several driving factors including growing prevalence of fungal infections such as candidiasis and aspergillosis, increasing popularity of over-the-counter drugs, and increase in availability of innovative antifungals. Moreover, increasing awareness regarding fatal antifungal diseases, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, growing scope in developing countries with large population such as China and India is anticipated to impel the market growth of the antifungal drugs market. However, growing portfolio of antifungal generic drugs, patent expiration of innovator drugs, increasing prevalence of fungal resistance, and counterfeit drugs are expected to hinder the market performance during forecasted period.
In this research report, the market is segmented on the basis of drug class and therapeutic indications. By drug class, the azoles class antifungals are predicted to hold their dominant position in the market. By therapeutic indications, drugs use in the treatment of candidiasis are anticipated to creates their dominance in global antifungal drugs market. Amongst the regions, North America accounts for the largest regional share in the global antifungal drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and highly advanced medical infrastructure.
The report titled “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, has covered and analysed the potential of antifungal drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antifungal drugs. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Antifungal Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antifungal Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
• Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
Regional Antifungal Drugs Market – North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antifungal Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
• Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
Country Analysis – U.S., Canada, Germany, U.K, France, China, Japan, India (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antifungal Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
• Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
Other Report Highlights
• Market Dynamics – Drivers and Restraints.
• Market Trends.
• Porter Five Forces Analysis.
• SWOT Analysis.
• Company Analysis - Merck & Co., Glaxo Smith Kline, Astellas Pharma, Sanofi, Abbott Laboratories, Bayer, Kramer Laboratories, Novartis International AG, Pfizer.
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
